Thomas Gustafson,

Vice President, Scientific Innovation, Cardiovascular & Metabolic Diseases

Gus is Vice President of Scientific Innovation for Cardiovascular & Metabolic diseases at Johnson & Johnson Innovation, California.  In this role, he uses his extensive background in diabetes and cardiovascular drug discovery to identify better treatments, and ideally cures, for metabolic disease such as Type 2 diabetes.

Previously, Gus was Site Lead at Merck where he led the Diabetes Department and he also served as Vice President at Pfizer where he led the CVMED Target Exploratory Unit. Earlier in his career, Gus served as Chief Scientific Officer at Eli Lilly and led the Diabetes “Drug Hunting Team.” Prior to industry, Gus enjoyed an academic career at the University of Maryland-Baltimore, publishing over 50 papers and achieving the rank of Associate Professor in the Department of Physiology.

Gus earned his BS in biology at the University of Wisconsin – Stevens Point, and a PhD in Pharmacology and Toxicology at the University of Arizona in Tucson.  He was a postdoctoral scholar at Stanford University and at UC-San Francisco.


Thomas Gustafson
Thomas Gustafson